MedPath
FDA Approval

ARIKAYCE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Insmed Incorporated
DUNS: 183470066
Effective Date
February 8, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Amikacin(590 mg in 8.4 mL)

Manufacturing Establishments8

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Wickham Micro Limited

Insmed Incorporated

228216353

ACS Dobfar S.p.A.

Insmed Incorporated

366662773

Resilience Biotechnologies Inc.

Insmed Incorporated

243669426

LabCorp Early Development Laboratories Limited

Insmed Incorporated

213137276

Alcami Carolinas Corporation

Insmed Incorporated

831351445

PPD Development Ireland Ltd

Insmed Incorporated

985036175

Sharp Packaging Services, LLC

Insmed Incorporated

143696495

Charles River Laboratories Ireland Limited

Insmed Incorporated

988712659

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ARIKAYCE

Product Details

NDC Product Code
71558-590
Application Number
NDA207356
Marketing Category
NDA (C73594)
Route of Administration
RESPIRATORY (INHALATION)
Effective Date
February 8, 2023
AmikacinActive
Code: 84319SGC3CClass: ACTIBQuantity: 590 mg in 8.4 mL
CholesterolInactive
Code: 97C5T2UQ7JClass: IACT
DIPALMITOYLPHOSPHATIDYLCHOLINE, DL-Inactive
Code: 2W15RT5V7VClass: IACT
Sodium HydroxideInactive
Code: 55X04QC32IClass: IACT
WaterInactive
Code: 059QF0KO0RClass: IACT
Sodium ChlorideInactive
Code: 451W47IQ8XClass: IACT
© Copyright 2025. All Rights Reserved by MedPath